Skip to main content
SpringerLink
Log in

Depression in Patients with Schizophrenia

Prevalence, and Diagnostic and Treatment Considerations

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Depression is a common comorbid syndrome in patients with schizophrenia. A review of the literature highlights the multitude of different expressions used to describe depression in this context. This fact exemplifies the diagnostic and therapeutic inconsistencies found in literature.

Former generations of psychiatrists considered that antidepressants could provoke psychotic symptoms. Although the evidence is still tentative, it appears to be current common practice for most psychiatrists, having ruled out confounding conditions such as extrapyramidal motor symptoms and negative symptoms, to prescribe antidepressant agents to patients who show depressive symptoms. There are controlled clinical trials that have demonstrated that tricyclic antidepressants are effective in the treatment of depression in patients with schizophrenia. In contrast, the newer antidepressants have yet to be tested in large scale controlled studies. Possible interactions between antipsychotics and antidepressants must be considered when these two classes of agent are prescribed.

Monotherapy with novel antipsychotics may be a treatment option, as some such as zotepine, olanzapine and risperidone have shown advantages over traditional antipsychotics in reducing depressive symptoms in patients with schizophrenia. Others have some pharmacological properties that resemble antidepressant drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

Similar content being viewed by others

References

  1. Kraepelin E. Dementia praecox and paraphrenia [1919; Barclay RM, translation]. Robertson GM, Krieger RE, editors. New York: Krieger Publishing; 1971

  2. Mayer-Gross W. Über die Stellungnahme zur abgelaufenen akuten psychose. Zeitsch Neurolog Psychiatrie 1920: 60: 160–212

    Google Scholar 

  3. Schneider K. Clinical Psychopathology (Hamilton WE, Anderson EW, translators). New York (NY): Grune and Stratton, 1959

    Google Scholar 

  4. Berner P, Katschnig H, Lenz G. Semiology and nosology. Acta Psychiatr Belg 1983; 3: 181–96

    Google Scholar 

  5. Heinrich K. Zur bedeutung des postremissiven erschöpfungs-syndroms für die rehabilitation schizophrener. Nervenarzt 1967; 38: 487–91

    PubMed  CAS  Google Scholar 

  6. Shanfield S, Tucker GJ, Harrow M, et al. The schizophrenic patient and depressive symptomatology. J Nerv Ment Dis 1970; 151: 203–10

    PubMed  CAS  Google Scholar 

  7. World Health Organization. International Classification of Disease (ICD-10): clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1988

    Google Scholar 

  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 711–2

    Google Scholar 

  9. Johnson DAW. Studies of depressive symptoms in schizophrenia. The prevalence of depression and its possible causes. Br J Psychiatry 1981; 139: 89–101

    PubMed  CAS  Google Scholar 

  10. Johnson DAW. Depressions in schizophrenia: some observations on prevalence, etiology, and treatment. Acta Psychiatr Scand Suppl 1981; 291: 137–44

    PubMed  CAS  Google Scholar 

  11. Knights A, Hirsch SR. Revealed depression and drag treatment for schizophrenia. Arch Gen Psychiatry 1981; 38: 806–11

    PubMed  CAS  Google Scholar 

  12. Möller HJ, von Zerssen D. Depressive states occurring during the neuroleptic treatment of schizophrenia. Schizophr Bull 1982; 8: 109–17

    PubMed  Google Scholar 

  13. McGlashan TH, Carpenter WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33: 231–9

    PubMed  CAS  Google Scholar 

  14. Wise RA. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 1982; 5: 39–87

    Google Scholar 

  15. Glimcher P, Margolin D. Dopamine pathways. Brain Res 1986; 266: 348–52

    Google Scholar 

  16. Harrow M, Yonan CA, Sands JR, et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994; 20: 327–38

    PubMed  CAS  Google Scholar 

  17. Helmchen H, Hippius H. Depressive syndrome im verlauf neuroleptischer therapie. Nervenarzt 1967; 38: 455–8

    PubMed  CAS  Google Scholar 

  18. De Alarcon R, Carney MWP. Severe depressive mood changes following slow release intramuscular fluphenazine injection. Br Med J 1969; 3(670): 564–7

    PubMed  Google Scholar 

  19. Floru L, Heinrich K, Witlek F. The problem of postpsychotic schizophrenic depressions and their pharmacological induction. Int Pharmacopsychiatry 1975; 10: 230–9

    PubMed  CAS  Google Scholar 

  20. Ananth J, Charidian AM. Drug induced mood disorder. Int Pharmacopsychiatry 1980; 15: 58–73

    Google Scholar 

  21. Müller P. Depressive syndrome im verlauf schizophrener psychosen. Stuttgart: Enke, 1981

    Google Scholar 

  22. Galdi J. The causality of depression in schizophrenia. Br J Psychiatry 1983; 142: 621–5

    PubMed  CAS  Google Scholar 

  23. Hirsch SR, Jolley AG, Barnes TRE, et al. Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res 1989; 2: 259–64

    PubMed  CAS  Google Scholar 

  24. Barnes TRE, Curson DA, Liddle PF, et al. The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 1989; 154: 486–91

    PubMed  CAS  Google Scholar 

  25. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science Ltd, 1995: 128–45

    Google Scholar 

  26. Van Putten T, May PRA. Akinetic depression in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101–7

    PubMed  Google Scholar 

  27. Bleuler E. Dementai praecox oder die Gruppe der Schizophrenen. Leipzig: Deuticke 1911

    Google Scholar 

  28. Vaillant G. Prospective prediction of schizophrenic remission. Arch Gen Psychiatry 1964; 11: 509–18

    PubMed  CAS  Google Scholar 

  29. Hoedemaker FS. Postpsychotic episodes and postpsychotic depression in young adults. Am J Psychiatry 1970; 127: 606–10

    PubMed  CAS  Google Scholar 

  30. Taylor M, Abrams R. Manic-depressive illness and good-prognosis schizophrenia. Am J Psychiatry 1975; 132: 741–5

    PubMed  CAS  Google Scholar 

  31. Mandel MR, Severe JB, Schooler NR. Development and prediction of postpsychotic depression in neuroleptic treated schizophrenics. Arch Gen Psychiatry 1982; 39: 197–203

    PubMed  CAS  Google Scholar 

  32. Johnson DAW. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988; 152: 320–3

    PubMed  CAS  Google Scholar 

  33. Falloon I, Watt DC, Shepherd MA. comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978; 8: 59–70

    PubMed  CAS  Google Scholar 

  34. Himmelhoch JM, Fuchs CZ, May SJ. When a schizoaffective diagnosis has meaning. J Nerv Ment Dis 1981; 169: 277–82

    PubMed  CAS  Google Scholar 

  35. Glazer W, Prusoff B, John K. Depression and social adjustment among chronic schizophrenic outpatients. J Nerv Ment Dis 1981; 169: 712–7

    PubMed  CAS  Google Scholar 

  36. Roy A. Suicide in chronic schizophrenia. Br J Psychiatry 1982; 141: 171–7

    PubMed  CAS  Google Scholar 

  37. Drake RE, Cotton PG. Depression, hopelessness and suicide in chronic schizophrenia. Br J Psychiatry 1986; 148: 554–9

    PubMed  CAS  Google Scholar 

  38. Herz M. Prodromal symptoms and prevention of relapse in schizophrenia. J Clin Psychiatry 1985; 46: 22–5

    PubMed  CAS  Google Scholar 

  39. Drake RE, Gates C, Whitaker A. Suicide among schizophrenics: a review. Compr Psychiatry 1985; 26: 90–100

    PubMed  CAS  Google Scholar 

  40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980

    Google Scholar 

  41. Radomsky ED, Haas GL, Mann JJ, et al. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am J Psychiatry 1999; 156(10): 1590–5

    PubMed  CAS  Google Scholar 

  42. Hirsch SR, Jolley AG. The dysphoric syndrome in schizophrenia and its implications for relapse. Br J Psychiatry 1989; 155: 46–50

    Google Scholar 

  43. Gross G, Huber G. Depressive syndrome im verlauf von Schizophrenien. Fortschr Neurol Psychiatr 1980; 48: 438–46

    CAS  Google Scholar 

  44. Sands J, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull 1999; 25: 157–71

    PubMed  CAS  Google Scholar 

  45. Martin RL, Cloninger RC, Guze SB, et al. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985; 46: 9–13

    PubMed  CAS  Google Scholar 

  46. Kibel DA, Laffont I, Liddle PF. The composition of the negative syndrome of chronic schizophrenia. Br J Psychiatry 1993; 162: 744–50

    PubMed  CAS  Google Scholar 

  47. Liddle PF, Barnes RE. The subjective experience of deficits in schizophrenia. Compr Psychiatry 1988; 29(2): 157–64

    PubMed  CAS  Google Scholar 

  48. Newcomer JW, Faustman WO, Yeh W, et al. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res 1990; 31(3): 243–50

    PubMed  CAS  Google Scholar 

  49. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3(4): 247–51

    PubMed  CAS  Google Scholar 

  50. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 1996; 19(2-3): 205–12

    PubMed  CAS  Google Scholar 

  51. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Scale for schizophrenics. Schizophr Res 1994; 11(3): 239–44

    PubMed  CAS  Google Scholar 

  52. Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992; 6(3): 201–8

    PubMed  CAS  Google Scholar 

  53. Collins AA, Remington G, Coulter K, et al. Depression in schizophrenia: a comparison of three measures. Schizophr Res 1996; 20(1-2): 205–9

    PubMed  CAS  Google Scholar 

  54. Heinrich K. Die gezielte Symptomprovokation mit monoamino-oxydasehemmenden Substanzen in diagnostik und therapie schizophrener psychosen. Nervenarzt 1960; 31: 507–72

    PubMed  CAS  Google Scholar 

  55. Klein DF, Fink M. Psychiatric reaction pattern to imipramine. Am J Psychiatry 1962; 119:432–8

    PubMed  CAS  Google Scholar 

  56. Klieser E. Experimentelle Untersuchung zur differentialindikation von neuroleptika und thymoleptika. Düsseldorf: Habilitationsschrift, 1988

    Google Scholar 

  57. Pollack M, Klein DF, Willner A. Imipramine-induced behavioral disorganisation in schizophrenic patients. Recent Adv Biol Psychiatry 1965; 7: 53–61

    Google Scholar 

  58. Becker RE. Depression in schizophrenia. Hosp Community Psychiatry 1988; 39: 1269–75

    PubMed  CAS  Google Scholar 

  59. Prussoff BA, Williams DH, Weismann MM. Treatment of secondary depression in schizophrenia: a doubleblind, placebo-controlled trial of amitriptyline added to perphenazine. Arch Gen Psychiatry 1979; 36: 569–75

    Google Scholar 

  60. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in ‘depressed’ schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry 1989; 46(10): 922–8

    PubMed  CAS  Google Scholar 

  61. Waehrens J, Gerlach J. Antidepressant drugs in anergic schizophrenia: a double-blind cross-over study with maprotiline and placebo. Acta Psychiatr Scand 1980; 61: 438–44

    PubMed  CAS  Google Scholar 

  62. Michaux MH, Kurland AA, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized acutely ill psychiatric patients. Curr Ther Res 1966; 8: 117–52

    PubMed  Google Scholar 

  63. Hanlon TE, Ota KY, Kurland AA. Comparative effects of fluphenazine, fluphenazine-chlodiazepoxide and fluphenazine-imipramine. Dis Nerv Syst 1970; 31: 171–7

    PubMed  CAS  Google Scholar 

  64. Hedberg DL, Houck JH, Glueck Jr BC. Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 1971; 127: 1141–6

    PubMed  CAS  Google Scholar 

  65. Kurland AA, Hanlon TE, Ota KY. Combinations of psychotherapeutic drugs in the treatment of the acutely disturbed psychiatric patient. In: Vinar O, Votava Z, Bradley PB, editors. Advances in neuropsychopharmacology. Amsterdam: North Holland Publishing Co., 1971: 419–24

    Google Scholar 

  66. Pishkin V. Concept identification and psychophysiological parameters in depressed schizophrenics as functions of imipramine and nialamide. J Clin Psychol 1972; 28: 335–9

    PubMed  CAS  Google Scholar 

  67. Chouinard G, Annable L, Serrano M, et al. Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. Arch Gen Psychiatry 1975; 32: 1295–307

    PubMed  CAS  Google Scholar 

  68. Kris EB, Gerst D. Combined perphenazine-amitriptyline as adjuvant therapy in psychiatric aftercare. Am J Psychiatry 1964; 121: 176–80

    Google Scholar 

  69. Cheng SF, Fogel EJ. Trifluoperazine combined with amitriptyline in paranoid psychosis. Am J Psychiatry 1963; 119: 780–1

    PubMed  CAS  Google Scholar 

  70. Kramer JC, Klein DF, Fink M. Imipramine as an adjunct to phenothiazine therapy. Compr Psychiatry 1962; 3: 377–80

    PubMed  CAS  Google Scholar 

  71. Hollister LE, Overall JE, Meyer F, et al. Perphenazine combined with amitriptyline in newly admitted schizophrenics. Am J Psychiatry 1963; 120: 591–2

    PubMed  CAS  Google Scholar 

  72. Dorfman W. Combined drug treatment. Am J Psychiatry 1963; 120: 275–6

    Google Scholar 

  73. Karacan I, Jones F, Ersevim I. Evaluation of combined antidepressant and tranquilizing drug (amitriptyline-perphenazine) in the treatment of hospitalized chronic schizophrenic patients. Am J Psychiatry 1963; 120: 500–1

    PubMed  CAS  Google Scholar 

  74. Pennington VM. The phrenotropic action of perphenazine-amitriptyline. Am J Psychiatry 1964; 120: 1115–6

    PubMed  CAS  Google Scholar 

  75. Smith E, Incas J. Combined amitriptyline and perphenazine in the treatment of severe emotional disorders. Int J Neuropsychiatry 1965; 1: 220–3

    Google Scholar 

  76. Feldman PE. Combined antidepressant-tranquilizer therapy of mixed psychiatric syndromes. Psychosomatics 1965; 6: 312–5

    PubMed  CAS  Google Scholar 

  77. Palestine ML. Desimipramine in the treatment of long standing psychotic disorders. Dis Nerv Syst 1965; 26: 176–80

    PubMed  CAS  Google Scholar 

  78. Bowers Jr MB, Astrachan BM. Depression in acute schizophrenic psychosis. Am J Psychiatry 1967; 123: 976–9

    PubMed  Google Scholar 

  79. Kennedy RE, Miller JJ. Amitriptyline-perphenazine in the treatment of schizophrenia. Am J Psychiatry 1963; 119: 1092–3

    PubMed  CAS  Google Scholar 

  80. Rada RT, Donlon PJ. Depression and the acute schizophrenic process. Psychosomatics 1975; 16: 116–9

    PubMed  CAS  Google Scholar 

  81. Gibbon J. Some examples of the combined use of psychotropic agents. Dis Nerv Syst 1961; 22(2 Suppl.): 81–5

    PubMed  Google Scholar 

  82. Ayd FJ. Amitriptyline: repraisal after six years’ experience. Dis Nerv Syst 1965; 26: 719–27

    PubMed  Google Scholar 

  83. Bowes HA. Amitriptyline, perphenazine and psychotherapy: Combined therapy in 800 patients over four years. Psychosomatics 1967; 8: 1–3

    PubMed  CAS  Google Scholar 

  84. Keskiner A. A long term follow up of fluphenazine enanthrate treatment. Curr Ther Res 1973; 15: 305–13

    PubMed  CAS  Google Scholar 

  85. Hogarty GE, McEvoy JP, Ulrich RF, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52(1): 29–41

    PubMed  CAS  Google Scholar 

  86. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17: 649–57

    PubMed  CAS  Google Scholar 

  87. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156(8): 1138–48

    PubMed  CAS  Google Scholar 

  88. Lerner Y, Mintzer Y, Schestatzky M. Lithium combined with haloperidol in schizophrenic patients. Br J Psychiatry 1988; 153: 359–62

    PubMed  CAS  Google Scholar 

  89. Salokangas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175–80

    PubMed  CAS  Google Scholar 

  90. Meyer MC, Baldessarini RJ, Goff DC, et al. Clinically significant interactions of psychotic agents with antipsychotic drugs. Drug Saf 1996; 15: 333–46

    PubMed  CAS  Google Scholar 

  91. Rasheed A, Javed MA, Nazir S, et al. Interaction of chlorpromazine with tricyclic antidepressants in schizophrenic patients. J Pakistani Med Ass 1994; 44: 233–4

    CAS  Google Scholar 

  92. Loga S, Curry C, Lader M. Interaction of chlorpromazine and nortriptyline in patients with schizophrenia. Clin Pharmaco-kinetics 1981; 6: 454–62

    CAS  Google Scholar 

  93. Gram LF, Overo KF. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972; 1(798): 463–5

    PubMed  CAS  Google Scholar 

  94. Nelson JC, Jatlow PI. Neuroleptic effect on desipramine steady-state plasma concentrations. Am J Psychiatry 1980; 137(10): 1232–4

    PubMed  CAS  Google Scholar 

  95. Siris SG, Cooper TB, Rifkin AE, et al. Plasma imipramine concentrations in patients receiving concomitant fluphenacine decanoate. Am J Psychiatry 1982; 139: 104–6

    PubMed  CAS  Google Scholar 

  96. Hiemke C, Weigmann H, Härtter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279–81

    PubMed  CAS  Google Scholar 

  97. Centorrino F, Baldessarini RJ, Kando J, et al. Clozapine and metabolites: serum concentrations and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 4: 119–25

    Google Scholar 

  98. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serotonin reuptake inhibitors alter metabolism of clozapine. Am J Psychiatry 1996; 153: 820–2

    PubMed  CAS  Google Scholar 

  99. Haring C, Neudorfer C, Schwitzer J, et al. EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology 1994; 114: 97–100

    PubMed  CAS  Google Scholar 

  100. Hummer M, Kemmler G, Kurz M, et al. Sexual disturbances during clozapine and haloperidol treatment. Am J Psychiatry 1999; 156: 631–3

    PubMed  CAS  Google Scholar 

  101. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994; 55Suppl. B: 78–81

    PubMed  Google Scholar 

  102. Own JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, netazodone and mirtazapine. Depress Anxiety 1998; 7(1): 34–6

    Google Scholar 

  103. Stahl SM. Psychopharmacology of antipsychotics. London: UK Martin Dunitz, 1999

    Google Scholar 

  104. Kanba S, Yagi G, Oguchi E, et al. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain. Jpn J Psychiatr Neurol 1991; 45: 133–4

    CAS  Google Scholar 

  105. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403–10

    PubMed  CAS  Google Scholar 

  106. Rowley HL, Kilpatrick IC, Needham PL, et al. Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropharmacology 1998; 37: 937–44

    PubMed  CAS  Google Scholar 

  107. Firschman A, Williams SA, Drury C, et al. Sustained 5-HT2 receptor occupancy of ziprasidone using the PET ligand setoperone in healthy volunteers [poster]. Presented at the XXth CINP congress: 1996 Jun 23–27; Melbourne

  108. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88.059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13

    PubMed  CAS  Google Scholar 

  109. Wolfersdorf M, König F, Straub R, et al. Delusional depression: treatment with zotepine or haloperidol and antidepressants. Psychopharmacopsychiatry 1993; 26: 215

    Google Scholar 

  110. Keck Jr PE, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140(2): 173–84

    CAS  Google Scholar 

  111. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind placebo and haloperidol controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466–74

    PubMed  CAS  Google Scholar 

  112. Peuskens J, Lemmens P, Van Baelen B. Effects of Risperidone on affective symptoms in patients with schizophrenia. 36th Annual Meeting of the American College of Neuropsycho-pharmacology: 1997 Dec 8–12; Kamuela (HI)

  113. Keck PE, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders. J Clin Psychiatry 1995; 56: 466–70

    PubMed  Google Scholar 

  114. Keck Jr PE, Strakowski SM, McElroy SM. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61(3): 4–9

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Psychiatry, Innsbruck University Hospital, Innsbruck, Austria

    Armand Hausmann

  2. Department of Biological Psychiatry, Innsbruck University Hospital, Innsbruck, Austria

    W. Wolfgang Fleischhacker

Authors
  1. Armand Hausmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Wolfgang Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armand Hausmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hausmann, A., Fleischhacker, W.W. Depression in Patients with Schizophrenia. Mol Diag Ther 14, 289–299 (2000). https://doi.org/10.2165/00023210-200014040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200014040-00004

Keywords

Search

Navigation